SD 0006
SD-06
CAS: 271576-80-8
Molecular Formula: C20H20ClN5O2
SD 0006 - Names and Identifiers
SD 0006 - Physico-chemical Properties
| Molecular Formula | C20H20ClN5O2 |
| Molar Mass | 397.86 |
| Density | 1.367 |
| Boling Point | 652.6±55.0 °C(Predicted) |
| Solubility | DMSO: ≥ 29 mg/mL |
| pKa | 9.39±0.50(Predicted) |
| Storage Condition | 2-8°C |
| In vitro study | SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate. |
| In vivo study | SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy. SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling. Animal Model: 8- to 12-week-old DBA/1 mice. Dosage: 3.75, 7.5 and 15 mg/kg. Administration: Orally twice daily. Result: Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density. |
SD 0006 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.513 ml | 12.567 ml | 25.135 ml |
| 5 mM | 0.503 ml | 2.513 ml | 5.027 ml |
| 10 mM | 0.251 ml | 1.257 ml | 2.513 ml |
| 5 mM | 0.05 ml | 0.251 ml | 0.503 ml |
Last Update：2024-01-02 23:10:35
SD 0006 - Reference Information
| biological activity | SD 0006 (SD-06) is an orally effective, selective, ATP competitive, and effective diarylpyrazole inhibitor of p38α MAPK with an IC50 value of 110 nM. |
| target | IC50: 110 nM (p38 MAPK). |
| in vitro study | SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate. |
| in vivo study | SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy. SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; B. I. d.) is highly effective in attenuating SCW-induced inflammation as shown by the pose-dependent inhibition of paw swelling. Animal Model: 8- to 12-week-old DBA/1 MICE. Dosage: 3.75, 7.5 and 15 mg/kg. Administration: Orally two daily. Result: inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density. |
| Animal Model: | 8- to 12-week-old DBA/1 mice. |
| Dosage: | 3.75, 7.5 and 15 mg/kg. |
| Administration: | Orally twice daily. |
| Result: | Inhibited the transcription of several inflammatory mediators to prevent joint swelling and bone destruction and to preserve bone density. |
Last Update：2024-04-09 15:16:38
Supplier List
Spot supply
Product Name: SD-06 Visit Supplier Webpage Request for quotationCAS: 271576-80-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: SD-06 Visit Supplier Webpage Request for quotationCAS: 271576-80-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History